Nexalin Technology (NXL) Expected to Post Quarterly Earnings on Friday

Nexalin Technology (NASDAQ:NXL) is expected to be posting its Q3 2026 results on Friday, November 13th. Analysts expect the company to announce earnings of ($2.91) per share and revenue of $0.07 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 18, 2026 at 4:00 PM ET.

Nexalin Technology (NASDAQ:NXL) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($3.00) by $2.89. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.09 million. Nexalin Technology had a negative net margin of 4,141.94% and a negative return on equity of 278.24%. On average, analysts expect Nexalin Technology to post ($11.42) EPS for the current fiscal year and ($7.55) EPS for the next fiscal year.

Nexalin Technology Stock Performance

Shares of Nexalin Technology stock opened at $1.59 on Thursday. The firm’s 50-day simple moving average is $3.51 and its 200-day simple moving average is $10.26. Nexalin Technology has a 1 year low of $1.31 and a 1 year high of $39.30.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on NXL shares. Weiss Ratings downgraded Nexalin Technology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 25th. Zacks Research upgraded Nexalin Technology to a “hold” rating in a research note on Thursday, October 1st. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Reduce”.

About Nexalin Technology

Nexalin Technology, Inc. (NASDAQ:NXL) is a medical technology company focused on developing and commercializing noninvasive neurostimulation devices for mental health and neurological applications. Its technology is designed to deliver low-intensity electrical stimulation to the brain with the goal of influencing neural activity associated with conditions such as depression, anxiety, insomnia, post-traumatic stress disorder and substance-use disorders. The company’s product portfolio includes the Gen-2 and Gen-3 neurostimulation systems.